ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase I Clinical Study

ContraFect, Corp. announced that the US FDA completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, and concluded that the company may proceed with its Phase I clinical study.